Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 05/06/26
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingPRNewsWire • 05/01/26
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingPRNewsWire • 04/10/26
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines TranscriptSeeking Alpha • 03/25/26
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)PRNewsWire • 03/23/26
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030PRNewsWire • 03/19/26
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug researchReuters • 03/12/26
AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.Barrons • 02/27/26
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/26/26
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of PresbyopiaPRNewsWire • 02/25/26
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/23/26
What's in Store for These 5 Medical Companies This Earnings Season?Zacks Investment Research • 02/23/26
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash GenerationSeeking Alpha • 02/20/26